Premium
DNA polymorphisms of apolipoprotein B and AI/CIII genes and response to gemfibrozil treatment
Author(s) -
AaltoSetälä Katriina,
Kontula Kimmo,
Mänttäri Matti,
Huttunen Jussi,
Manninen Vesa,
Koskinen Pekka,
Frick Heikki M
Publication year - 1991
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1991.126
Subject(s) - gemfibrozil , apolipoprotein b , medicine , hyperlipidemia , biology , allele , lipoprotein , endocrinology , cholesterol , apolipoprotein e , polymorphism (computer science) , triglyceride , apolipoprotein a1 , genetics , gene , diabetes mellitus , disease
Apolipoprotein B XbaI polymorphism and apolipoprotein AI/CIII SstI polymorphism have been found to be associated with variations in serum lipoprotein levels. We investigated whether these gene polymorphisms are involved in determining the lipid‐modulating action of gemfibrozil. Of the 221 male subjects with hyperlipidemia studied, 121 responded well to the treatment with more than a 25% reduction in the non‐high‐density lipoprotein cholesterol level, whereas 100 were nonresponders. Among responders, but not nonresponders, homozygosity for the apolipoprotein B X2 allele (XbaI site present) and heterozygosity for the apolipoprotein AI/CIII S2 allele (SstI site present) were associated with elevated baseline serum low‐density lipoprotein cholesterol and triglyceride levels, respectively. However, the hypolipidemic effect of gemfibrozil among the responders was independent of these gene polymorphisms. These data indicate that common polymorphisms of the apolipoprotein B and apolipoprotein AI/CIII gene loci influence serum lipid levels by mechanisms that are amenable to an intervention with gemfibrozil. Clinical Pharmacology and Therapeutics (1991) 50, 208–214; doi: 10.1038/clpt.1991.126